GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.
Ted W. Love, M.D.Location
UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Global Blood Therapeutics is implementing good security practices.
Read more about the latest issues in cybersecurity
Ransomware is a type of malicious software, or malware, designed to deny access to a computer ...
WannaCry is a ransomware cryptoworm cyber attack that targets computers running the Microsoft ...
Compare Global Blood Therapeutics's security performance with other companies